DekaBank Deutsche Girozentrale boosted its stake in shares of LivaNova PLC (NASDAQ:LIVN – Get Rating) by 32.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 33,000 shares of the company’s stock after buying an additional 8,000 shares during the period. DekaBank Deutsche Girozentrale owned approximately 0.06% of LivaNova worth $1,814,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of LIVN. Western Pacific Wealth Management LP purchased a new stake in LivaNova during the 3rd quarter valued at $44,000. Picton Mahoney Asset Management purchased a new stake in LivaNova during the 3rd quarter valued at $70,000. Wolverine Asset Management LLC grew its position in LivaNova by 35.3% in the 3rd quarter. Wolverine Asset Management LLC now owns 1,454 shares of the company’s stock valued at $73,000 after acquiring an additional 379 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in LivaNova in the 3rd quarter valued at $85,000. Finally, Pacer Advisors Inc. bought a new position in LivaNova in the 3rd quarter valued at $117,000. Hedge funds and other institutional investors own 98.89% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on the company. Barclays cut their price objective on LivaNova from $62.00 to $45.00 in a research report on Tuesday, April 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $77.00 price objective on shares of LivaNova in a research report on Monday. StockNews.com assumed coverage on LivaNova in a research report on Thursday, March 16th. They issued a “buy” rating on the stock. Finally, Mizuho assumed coverage on LivaNova in a research report on Thursday, April 13th. They issued a “neutral” rating and a $48.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $63.40.
LivaNova Price Performance
LivaNova (NASDAQ:LIVN – Get Rating) last issued its quarterly earnings data on Wednesday, February 22nd. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.09. LivaNova had a positive return on equity of 10.49% and a negative net margin of 8.44%. The company had revenue of $274.90 million for the quarter, compared to the consensus estimate of $262.16 million. During the same quarter last year, the company earned $0.57 earnings per share. The firm’s revenue for the quarter was up 1.8% compared to the same quarter last year. On average, equities research analysts anticipate that LivaNova PLC will post 2.58 earnings per share for the current fiscal year.
About LivaNova
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiopulmonary and Other segments. The Cardiopulmonary segment is involved in the development, production and sale of cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, and related accessories.
Featured Articles
- Get a free copy of the StockNews.com research report on LivaNova (LIVN)
- Finding New Technology to Invest in: A Guide
- Genuine Parts Company Is Genuinely A Good Buy
- Healthcare Sector: Overview and Keys to Investing
- Can D.R. Horton Shares Raise The Roof, Or Is This The Ceiling?
- American Express Growth Riding On Joyful Consumer Spending
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN – Get Rating).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.
